Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

MaxCyte board member Art Mandell retires

Published 12/23/2024, 02:04 AM

ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT; LSE:MXCT), a cell-engineering company focused on providing technologies for cell therapeutics, announced the retirement of Art Mandell from its Board of Directors, effective December 31, 2024. Mandell, who has been a part of the board since 2006, played a significant role in the company's growth, including its initial public offerings on the UK AIM exchange and the US Nasdaq, and the launch of its ExPERT™ platform.

The company credits Mandell for his leadership and contributions that helped position MaxCyte as a leader in cell engineering. Chairman Richard Douglas expressed gratitude for Mandell's "exceptional leadership, scientific insights and valuable contributions." Mandell commented on his departure, stating his pride in the company's achievements and his confidence in MaxCyte's future in providing technology solutions for cell and gene therapies.

MaxCyte's ExPERT™ platform is recognized for supporting the cell therapy market across various stages, from discovery to commercialization. The platform includes a range of instruments, proprietary disposables, and software protocols, backed by a global intellectual property portfolio.

This announcement is based on a press release statement and does not include any forward-looking statements or predictions of future events. The company has not disclosed plans for Mandell's successor or changes to the board's composition following his retirement. MaxCyte continues to focus on advancing cell-based medicines, as evidenced by its strategic platform licenses and support of the industry's first FDA-approved, CRISPR edited non-viral cell therapy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.